Comparative Effectiveness of Tezepelumab and Dupilumab in Asthma: A Multinational Retrospective Cohort Study
The Journal of Allergy and Clinical Immunology: In Practice · 2026-02 · 14 (2) · 427-435.e5
DOI: 10.1016/j.jaip.2025.11.024 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-02. Verfasst von Chun-Tse Hung und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Mich. Electronic address: b323106029@tmu.edu.tw. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Although both dupilumab and tezepelumab are approved for severe asthma, real-world evidence comparing their effectiveness remains limited. OBJECTIVE: To compare the effectiveness of tezepelumab versus dupilumab in reducing asthma exacerbations among patients with asthma. METHODS: Data were obtained from the Global Collaborative Network of TriNetX. Adults aged ≥18 years who initiated dupilumab or tezepelumab between December 17, 2021, and September 1, 2024, were included. The primary outcome was time to first asthma exacerbation, and the secondary outcome was systemic corticosteroid use. Both outcomes were assessed over 1 year. Subgroup analyses were conducted by blood eosinophil counts, presence of chronic obstructive pulmonary disease (COPD), prior biologics use, and obesity. Propensity score matching was used to balance covariates between groups. Kaplan-Meier curves and Cox regression models were used to estimate comparative effectiveness. RESULTS: After 1:1 matching, 688 matched patients were included in each group. In the matched cohorts, the risk of asthma exacerbation did not differ between dupilumab and tezepelumab (hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.83-1.10). This finding was consistent across sensitivity analyses. Both biologics showed similar benefits across all blood eosinophil levels and regardless of COPD, prior biologics use, or obesity. The risk of systemic corticosteroid use was also similar between both biologics (HR, 0.97; 95% CI, 0.85-1.10). CONCLUSION: No significant difference in exacerbation risk was found between dupilumab and tezepelumab. Because residual confounding may exist, further investigation is warranted to guide the selection of biological therapies in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Mich. Electronic address: b323106029@tmu.edu.tw.
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Pharmacy, Taipei Medical University Hospital, Taipei, Taiwan.
- Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Zitieren
APA
Hung, C. T., Hung, Y. C., An, C. Y., & Suk, C. W. (2026). Comparative Effectiveness of Tezepelumab and Dupilumab in Asthma: A Multinational Retrospective Cohort Study. The Journal of Allergy and Clinical Immunology: In Practice, 14(2), 427-435.e5. https://doi.org/10.1016/j.jaip.2025.11.024
Vancouver
Hung CT, Hung YC, An CY, Suk CW. Comparative Effectiveness of Tezepelumab and Dupilumab in Asthma: A Multinational Retrospective Cohort Study. The Journal of Allergy and Clinical Immunology: In Practice. 2026;14(2):427-435.e5. doi:10.1016/j.jaip.2025.11.024
BibTeX
@article{Hung2026,
author = {Hung, Chun-Tse and Hung, Yu-Chien and An, Chen-Yen and Suk, Chi-Won},
title = {Comparative Effectiveness of Tezepelumab and Dupilumab in Asthma: A Multinational Retrospective Cohort Study},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2026},
volume = {14},
number = {2},
pages = {427--435.e5},
doi = {10.1016/j.jaip.2025.11.024}
}
EUVIMED